These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34307148)

  • 1. The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma.
    Pletcher JP; Bhattacharjee S; Doan JP; Wynn R; Sindhwani P; Nadiminty N; Petros FG
    Front Oncol; 2021; 11():681441. PubMed ID: 34307148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.
    Bhattacharjee S; Sullivan MJ; Wynn RR; Demagall A; Hendrix AS; Sindhwani P; Petros FG; Nadiminty N
    BMC Cancer; 2022 Mar; 22(1):312. PubMed ID: 35321693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
    Heitmann J; Geeleher P; Zuo Z; Weichselbaum RR; Vokes EE; Fetscher S; Seiwert TY
    Oral Oncol; 2014 Sep; 50(9):825-31. PubMed ID: 25017803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    Boussios S; Moschetta M; Karihtala P; Samartzis EP; Sheriff M; Pappas-Gogos G; Ozturk MA; Uccello M; Karathanasi A; Tringos M; Rassy E; Pavlidis N
    Ann Transl Med; 2020 Dec; 8(24):1706. PubMed ID: 33490218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    Nizialek E; Antonarakis ES
    Cancer Manag Res; 2020; 12():8105-8114. PubMed ID: 32982407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 12. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
    Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
    Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
    Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veliparib: a new therapeutic option in ovarian cancer?
    Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
    Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 17. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
    Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 20. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.